A bioresponsive genetically encoded antimicrobial crystal for the oral treatment of helicobacter pylori Infection
Author(s)
Author(s)
Zhang, W.
Yang, Z.
Zheng, J.
Fu, K.
Ni, Y.
Ng, T. B.
Cho, C. H.
Chan, M. K.
Lee, M. M.
Date Issued
2023
Publisher
John Wiley & Sons
Journal
Advanced Science
Volume
10
Issue
30
Abstract
Helicobacter pylori (H. pylori) causes infection in the stomach and is a major factor for gastric carcinogenesis. The application of antimicrobial peptides (AMPs) as an alternative treatment to traditional antibiotics is limited by their facile degradation in the stomach, their poor penetration of the gastric mucosa, and the cost of peptide production. Here, the design and characterization of a genetically encoded H. pylori-responsive microbicidal protein crystal Cry3Aa-MIIA-AMP-P17 is described. This designed crystal exhibits preferential binding to H. pylori, and when activated, promotes the targeted release of the AMP at the H. pylori infection site. Significantly, when the activated Cry3Aa-MIIA-AMP-P17 crystals are orally delivered to infected mice, the Cry3Aa crystal framework protects its cargo AMP against degradation, resulting in enhanced in vivo efficacy against H. pylori infection. Notably, in contrast to antibiotics, treatment with the activated crystals results in minimal perturbation of the mouse gut microbiota. These results demonstrate that engineered Cry3Aa crystals can serve as an effective platform for the oral delivery of therapeutic peptides to treat gastrointestinal diseases.
SFU Affiliated Publication
No
Availability at SFU Library
No database links found.